FY2025 EPS Estimates for Moderna Reduced by Leerink Partnrs

Moderna, Inc. (NASDAQ:MRNA) – Research analysts at Leerink Partnrs dropped their FY2025 EPS estimates for Moderna in a report issued on Sunday, November 17th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($9.90) per share for the year, down from their previous estimate of ($9.89). The consensus estimate for Moderna’s current full-year earnings is ($9.44) per share.

Other equities research analysts have also issued reports about the stock. UBS Group lowered their price objective on shares of Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Jefferies Financial Group reduced their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday. Finally, Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and dropped their target price for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Moderna has a consensus rating of “Hold” and an average price target of $84.00.

Moderna Stock Performance

NASDAQ:MRNA opened at $38.40 on Wednesday. The company has a market capitalization of $14.78 billion, a price-to-earnings ratio of -6.35 and a beta of 1.69. The business has a 50 day moving average of $56.13 and a 200 day moving average of $95.05. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna has a 1-year low of $35.80 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.39) earnings per share.

Institutional Trading of Moderna

Large investors have recently made changes to their positions in the stock. Ashton Thomas Private Wealth LLC bought a new stake in Moderna in the 2nd quarter worth approximately $26,000. Family Firm Inc. bought a new stake in shares of Moderna in the second quarter worth $33,000. Bank & Trust Co purchased a new stake in Moderna during the second quarter valued at $36,000. Hanseatic Management Services Inc. bought a new position in Moderna in the second quarter valued at about $48,000. Finally, Plato Investment Management Ltd boosted its position in Moderna by 230.4% in the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after purchasing an additional 288 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 2,930 shares of company stock valued at $217,170 over the last 90 days. Corporate insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.